Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Значение результатов недавних клинических исследований для рекомендаций III группы экспертов по лечению взрослых Национальной образовательной программы по холестерину
2004-07-12
SCID: 54.1/cm7m494z
Discuss with AI
ATP III guidelinesLDL cholesterolclinical trialsstatin therapytherapeutic lifestyle changes
Figures from the paper
Abstract (AI)
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Key Findings
1
Five major post-ATP III statin trials confirmed the benefit of cholesterol-lowering therapy in high-risk patients and supported an LDL-C goal below 100 mg/dL.
2
For moderately high-risk patients, LDL-C below 100 mg/dL is a therapeutic option, including those with baseline LDL-C of 100–129 mg/dL; combination therapy may be considered with high triglycerides or low HDL-C.
3
For very-high-risk patients, an LDL-C goal below 70 mg/dL is a reasonable therapeutic option, including when baseline LDL-C is below 100 mg/dL.
4
Older adults also benefit from therapeutic LDL-C reduction, supporting treatment in this age group.
5
The evidence supports classifying patients with diabetes as high risk and confirms benefits from LDL-C-lowering therapy in this population.
6
Therapeutic lifestyle changes remain an essential component of cholesterol management.
Research Object
ATP III cholesterol-management guidelines (National Cholesterol Education Program Adult Treatment Panel III) and their applicability based on recent clinical statin trials
Research Subject
Implications of recent statin clinical-trial evidence for LDL-C treatment goals and cholesterol-management strategies
Publication Details
Publication Date
2004-07-12
Journal
Publisher
ISSN
Cited by
6883
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by17
2013 ACCF/AHA Guideline for the Management of Heart Failure2013
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement2005
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes2015
Standards of Medical Care in Diabetes—20132012
Forecasting the Future of Cardiovascular Disease in the United States2011
Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association2013
Standards of Medical Care in Diabetes—20122011
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction2007
Statins for the primary prevention of cardiovascular disease2013
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials2009
Prevention of Heart Failure2008
The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates2014
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management2011
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult2005